• Black JL, Ge Q, Boustany S, Johnson PRA, Poniris MH, Glanville AR et al. (2005). In vitro studies of lymphangioleiomyomatosis. Eur Respir J 26: 569576.
  • Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM et al. (2000). MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 123: 259267.
  • Chang WY, Clements D, Johnson SR (2010). Effect of doxycycline on proliferation, MMP production and adhesion in LAM related cells. Am J Physiol Lung Cell Mol Physiol 299: L393L400.
  • Franco C, Ho B, Mulholland D, Hou G, Islam M, Donaldson K et al. (2006). Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am J Pathol 168: 16971709.
  • Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS et al. (2002). Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 277: 3095830967.
  • Goncharova EA, Goncharov DA, Spaits M, Noonan D, Talovskaya E, Eszterhas A et al. (2006). Abnormal smooth muscle cell growth in lymphangioleiomyomatosis (LAM): role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 34: 561572.
  • Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM et al. (1998). Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 12: 114118.
  • Hashimoto T, Matsumoto MM, Li JF, Lawton MT, Young WL (2005). Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurol 5: 1.
  • Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ et al. (1997). Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis. Hum Pathol 28: 10711078.
  • Johnson PR, Roth M, Tamm M, Hughes M, Ge Q, King G et al. (2001). Airway smooth muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med 164: 474477.
  • Ko FW, Diba C, Roth M, McKay K, Johnson PR, Salome C et al. (2005). A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest 127: 19191927.
  • Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R et al. (2010). Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol 42: 227234.
  • Li DQ, Shang TY, Kim HS, Solomon A, Lokeshwar BL, Pflugfelder SC (2003). Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci 44: 29282936.
  • McCormack F, Brody A, Meyer C, Leonard J, Chuck G, Dabora S et al. (2002). Pulmonary cysts consistent with lymphangioleiomyomatosis are common in women with tuberous sclerosis: genetic and radiographic analysis. Chest 121: 61S.
  • Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ (2000). Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124: 267275.
  • Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J (1999). Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 21: 327336.
  • Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ (2002). Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest 122: 15431552.
  • Merrilees MJ, Hankin EJ, Black JL, Beamont B (2003). Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis. J Pathol 203: 653660.
  • Moir LM, Burgess JK, Black JL (2008). Transforming growth factor beta(1) increases fibronectin deposition through integrin receptor alpha(5)beta(1) on human airway smooth muscle. J Allergy Clin Immunol 121: 10341039 e4.
  • Moses MA, Harper J, Folkman J (2006). Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 354: 26212622.
  • Odajima N, Betsuyaku T, Nasuhara Y, Inoue H, Seyama K, Nishimura M (2009). Matrix metalloproteinases in blood from patients with LAM. Respir Med 103: 124129.
  • Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW et al. (2002). Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 35: 923929.
  • Rubins JB, Charboneau D, Alter MD, Bitterman PB, Kratzke RA (2001). Inhibition of mesothelioma cell growth in vitro by doxycycline. J Lab Clin Med 138: 101106.
  • Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP (1998). Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62: 810815.
  • Tamargo RJ, Bok RA, Brem H (1991). Angiogenesis inhibition by minocycline. Cancer Res 51: 672675.
  • Zhe X, Yang Y, Jakkaraju S, Schuger L (2003). TIMP-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal SRF expression. Am J Respir Cell Mol Biol 28: 504511.